Share: Facebook Twitter LinkedIn
Activity Provided By:

i3 Health

Update on Immunotherapeutic Strategies for Advanced Merkel Cell Carcinoma

Access Activity

Overview / Abstract:


Merkel cell carcinoma is a rare and aggressive neuroendocrine tumor of unknown origin that typically presents in older white and immunocompromised adults. An estimated 2,488 cases are diagnosed in the United States annually (Paulson et al, 2018). The incidence of MCC has risen rapidly during the past few decades, which has been attributed in part to people living longer with increased sun exposure and weakened immune systems, a feature that suggests an infectious origin and warrants further research (NCCN, 2019). Treatment standards are lacking and consequently clinical decision making is often empirical rather than evidence-based. The mortality rate for MCC presently exceeds that of melanoma. The overall 5-year survival rate ranges from 41% to 77%, depending upon stage at presentation (NCCN, 2019).


Oncologists, dermatologists, oncology advanced practitioners, oncology nurses, and other health care professionals involved in the treatment of patients with Merkel cell carcinoma (MCC).


Upon completion of this activity, participants should be able to:

1.) Assess emerging evidence on immunotherapeutic strategies for advanced MCC
2.) Describe multidisciplinary approaches to monitor and manage immune-related adverse events in patients receiving treatment for advanced MCC

Also available as a podcast.


Jan 21, 2022


Nurse Practitioner , Nursing CNE, Physician CME, Physician Assistant CME


Online, Podcast, Webinar / Webcast / Video

Credits / Hours




Presenters / Authors / Faculty

Shailender Bhatia, MD
Associate Professor of Medicine
University of Washington School of Medicine

Ciara Kelly, MBBCh, BAO
Assistant Attending Physician, Sarcoma Medical Oncology Service
Memorial Sloan Kettering Cancer Center

Activity Specialities / Related Topics

Adverse Drug Reactions / ADR, Dermatology, Oncology / Cancer / Radiation Therapy

Sponsors / Supporters / Grant Providers

This activity is supported by an independent educational grant from Merck.

Keywords / Search Terms

i3 Health i3 Health, CME, NCPD, pharmacotherapy, free CME, free NCPD, free CE, CE, CNE, free CNE, oncology, Merkel cell carcinoma, MCC, dermatology Free CE CME

Access Activity

CORE Higher Education Group,, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the website or within our mobile apps.CORE Higher Education Group,, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the Terms of Service. Site Map